Depressive Disorders

116 questions

Question 61Question →

A 28-year-old woman presents to her primary care physician reporting a 6-week history of pervasive sadness, loss of interest in her usual hobbies, significant fatigue, and difficulty concentrating at work. She has no past medical history and takes no medications. Physical examination and initial laboratory studies, including a thyroid-stimulating hormone level, are unremarkable. The physician determines she meets the criteria for a major depressive episode and considers initiating a selective serotonin reuptake inhibitor. Which of the following is the most critical historical information to obtain before prescribing this medication?

Show answer & explanation

Answer: History of unusually elevated mood and decreased need for sleep

Answer

History of unusually elevated mood and decreased need for sleep
A major depressive episode is not exclusive to major depressive disorder; it also occurs in bipolar I and bipolar II disorders. Initiating an antidepressant, such as a selective serotonin reuptake inhibitor, without a concurrent mood stabilizer in a patient with bipolar disorder can precipitate a dangerous manic or hypomanic episode (a 'manic switch'). Therefore, inquiring about past periods of elevated mood, impulsivity, and a decreased need for sleep is the most critical safety screening step before prescribing any antidepressant.

Step-by-Step Solution

1
Identify the patient's current clinical syndrome.
The patient meets criteria for a major depressive episode.
She has 6 weeks of depressed mood, anhedonia, fatigue, and poor concentration.
2
Determine the necessary safety assessments prior to initiating an antidepressant.
The physician must screen for a history of mania or hypomania.
A major depressive episode can occur in both unipolar and bipolar disorders. Antidepressant monotherapy can trigger a manic switch in bipolar patients.

Key Concept

Before initiating antidepressant monotherapy for a major depressive episode, physicians must screen for a history of manic or hypomanic episodes to prevent iatrogenic precipitation of mania.
Question 62Question →

For each patient vignette describing a mood-related presentation, select the most appropriate primary treatment modality or specific medication.

Click a left item, then click its matching right item

Items

A 78-year-old retired architect presenting with profound psychomotor retardation, delusions that his organs are rotting, and complete refusal of food and water for five days.
A 54-year-old office manager who developed persistent anhedonia, early morning awakenings, and severe guilt three weeks after surviving an acute anterior myocardial infarction.
A 31-year-old freelance writer with current debilitating hypersomnia and low mood, whose medical records indicate a previous four-day episode of pressured speech and decreased need for sleep.
A 28-year-old physical therapist with a new-onset major depressive episode who explicitly requests a medication that will not cause weight gain or sexual dysfunction.

Matches

Show answer & explanation

Answer

The correct matches align specific clinical presentations of depression with their evidence-based treatments: severe inanition/psychosis with electroconvulsive therapy, post-myocardial infarction status with sertraline, bipolar depression with quetiapine, and concern for sexual side effects with bupropion.
Each match represents the standard of care for a specific depressive presentation. Electroconvulsive therapy is rapidly acting and life-saving for psychotic depression with inanition. Sertraline has the best cardiovascular safety profile for post-myocardial infarction patients. Quetiapine effectively treats bipolar depression without the risk of a manic switch associated with SSRI monotherapy. Bupropion is a norepinephrine-dopamine reuptake inhibitor that lacks the sexual dysfunction and weight gain typical of SSRIs.

Step-by-Step Solution

1
Analyze the 78-year-old patient's presentation.
Identified psychotic depression with life-threatening food and fluid refusal.
Dictates the need for a rapid, definitive intervention rather than waiting weeks for pharmacotherapy to take effect.
2
Evaluate the 54-year-old patient's medical history.
Noted the very recent acute anterior myocardial infarction.
Cardiovascular safety is the primary limiting factor when selecting an antidepressant for this patient population.
3
Review the 31-year-old patient's psychiatric history.
Identified a past hypomanic episode (4 days of decreased sleep and pressured speech).
Changes the diagnosis from unipolar to bipolar depression, fundamentally altering the pharmacologic approach.
4
Consider the 28-year-old patient's specific treatment preferences.
Identified the requirement to avoid weight gain and sexual dysfunction.
Guides the selection away from standard SSRIs toward an atypical agent with a different receptor profile.

Key Concept

Tailoring management of depressive disorders to patient-specific psychiatric comorbidities, medical history, and medication side effect profiles.
Question 63Question →

A 34-year-old man comes to the primary care clinic complaining of dizziness, nausea, vivid nightmares, and "electric shock-like" sensations in his head for the past 3 days. He has a history of major depressive disorder, which has been well-controlled on paroxetine for the past year. During the interview, he mentions that he felt completely back to normal, so he abruptly stopped taking his medication 4 days ago. His vital signs and physical examination are unremarkable. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Restart paroxetine and initiate a gradual tapering schedule

Answer

Restart paroxetine and initiate a gradual tapering schedule.
The correct action is to restart paroxetine and initiate a gradual tapering schedule. This patient is experiencing antidepressant discontinuation syndrome. This syndrome typically occurs within a few days of abruptly stopping a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI). It is particularly common with medications that have a short half-life and no active metabolites, such as paroxetine and venlafaxine. Classic symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances (often described as 'brain zaps' or electric shock-like sensations), and hyperarousal. The definitive treatment is to restart the discontinued medication, which usually resolves symptoms within 24 hours, followed by a gradual dose taper if the patient still wishes to discontinue the drug.

Step-by-Step Solution

1
Identify the underlying cause of the patient's acute symptoms.
The abrupt discontinuation of paroxetine has caused antidepressant discontinuation syndrome.
Symptoms such as dizziness, nausea, vivid dreams, and 'brain zaps' (electric shock sensations) emerging 1 to 4 days after stopping a short-acting SSRI are pathognomonic for this syndrome.
2
Determine the best therapeutic intervention.
Restart the paroxetine and then taper it slowly over several weeks.
Restarting the medication eliminates the withdrawal symptoms. A gradual taper gives the brain's serotonin receptors time to adapt, preventing the symptoms from recurring.

Key Concept

Antidepressant Discontinuation Syndrome
Question 64Question →

A 64-year-old man is evaluated in the outpatient clinic for a severe major depressive episode 3 months after suffering an acute anterior myocardial infarction. He is currently hemodynamically stable and compliant with his post-myocardial infarction medical regimen, which includes dual antiplatelet therapy. He reports pervasive anhedonia, early morning awakening, profound fatigue, and feelings of worthlessness. Over the subsequent 18 months, despite extensive medical management, his depressive disorder proves highly resistant to standard therapies, eventually precipitating a severe clinical deterioration characterized by extreme food refusal, profound dehydration, and catatonic posturing requiring emergent hospitalization.

Arrange the following psychiatric management steps in the most appropriate, evidence-based chronological sequence for this patient, from initial evaluation in the outpatient clinic to the management of his final acute decompensation.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Screen for a history of mania, 2) Initiate sertraline monotherapy, 3) Augment or switch antidepressants after initial monotherapy failure, 4) Administer urgent ECT for catatonia and life-threatening inanition.
The management of major depressive disorder follows a distinct, stepped-care algorithm. Initial evaluation must strictly rule out bipolar disorder before the commencement of antidepressant therapy to avoid manic switching. Once unipolar depression is confirmed, a first-line agent is initiated; in a post-myocardial infarction patient, sertraline is the safest choice due to its lack of significant cardiovascular or QTc-prolonging effects. If the patient fails to respond after an adequate 6-8 week trial at maximum tolerated doses, the regimen is escalated either by switching to another first-line agent or adding an augmenting medication like an atypical antipsychotic. Finally, if the patient develops life-threatening complications such as severe inanition, food refusal, or catatonia, rapid definitive intervention is required, making electroconvulsive therapy (ECT) the absolute treatment of choice regardless of prior medication failures.

Step-by-Step Solution

1
Rule out bipolar disorder.
Patient is confirmed to have unipolar major depressive disorder.
Antidepressant monotherapy in an undiagnosed bipolar patient can trigger an acute manic episode.
2
Select and initiate a safe first-line antidepressant based on comorbidities.
Sertraline is chosen and titrated to a therapeutic dose for an 8-week trial.
The patient's recent myocardial infarction dictates the use of sertraline, which has the safest post-MI cardiovascular profile compared to other SSRIs (like citalopram) or TCAs.
3
Escalate therapy due to treatment resistance.
The regimen is augmented with an atypical antipsychotic or transitioned to a different antidepressant class.
Standard stepped-care algorithms require changing the mechanism of action or augmenting when an adequate trial of initial monotherapy fails.
4
Implement definitive emergent somatic therapy.
The patient is hospitalized and receives ECT.
The progression to catatonia and severe food refusal is a life-threatening psychiatric emergency that requires the rapid response rate uniquely provided by ECT.

Key Concept

Stepped-care escalation of Major Depressive Disorder (MDD) in patients with cardiovascular comorbidities, culminating in emergent ECT for catatonia.
Question 65Question →

Match each patient's presentation of a depressive disorder or related mood disturbance with the most appropriate therapeutic intervention.

Click a left item, then click its matching right item

Items

A female patient in her early thirties is evaluated for profound sadness. Her psychiatric history includes a distinct 6-day period of reduced sleep, rapid speech, and impulsive behavior.
A male patient in his late sixties is admitted for a severe mood disorder. He refuses all oral intake, claiming his internal organs have decayed, leading to rapid physiological decline.
A young man who began taking sertraline for a first-episode major depressive disorder reports complete resolution of his symptoms after 6 weeks. He now strongly desires to stop taking the medication immediately.
A middle-aged woman with unipolar depression notes only a partial reduction in her symptoms despite completing an 8-week trial of fluoxetine at the maximum tolerated dosage.

Matches

Show answer & explanation

Answer

The correct pairings match each distinct clinical scenario to its evidence-based management: avoiding SSRI monotherapy for bipolar depression, utilizing ECT for life-threatening psychotic depression, ensuring a 4-to-9-month continuation phase to prevent early relapse, and utilizing augmentation for a partial SSRI response.
Each correct pairing applies foundational psychiatric management principles. Recognizing bipolar depression prevents the error of antidepressant monotherapy. Identifying life-threatening psychotic depression correctly prompts urgent ECT. Understanding the continuation phase of treatment prevents premature discontinuation. Recognizing partial response guides the choice of augmentation.

Step-by-Step Solution

1
Analyze the history of the female patient with reduced sleep and rapid speech.
The history confirms bipolar disorder rather than unipolar depression.
Screening for past hypomanic episodes is critical to avoid inappropriate antidepressant monotherapy.
2
Assess the severity and features of the older male patient's condition.
He exhibits psychotic features (somatic delusions) and life-threatening oral refusal.
These severe features mandate rapid intervention with ECT rather than waiting weeks for pharmacotherapy to take effect.
3
Determine the appropriate duration of therapy for the young man in remission.
Therapy must continue for 4 to 9 months beyond acute remission.
Premature discontinuation significantly increases the risk of an early relapse.
4
Formulate a plan for the middle-aged woman with partial SSRI response.
Augmentation is chosen over switching because she has shown some response and tolerates the medication.
Augmentation builds on the partial response without losing the progress already achieved.

Key Concept

Management of Depressive Disorders and Complications
Estimated Time:1m 30s
Question 66Question →

A 37-year-old man is brought to the clinic by his sister due to a 6-week history of profound fatigue, hypersomnia, and a 4-kg (9-lb) weight gain. He states he feels completely devoid of energy, struggles to get out of bed, and expresses unwarranted guilt over taking time off from his job as an accountant. His sister notes that three years ago, the patient experienced a highly unusual two-week period during which he slept only three hours a night, exhibited pressured speech, and impulsively emptied his savings account to invest in unproven cryptocurrency. He has no other medical history and takes no medications. Vital signs are within normal limits. Laboratory evaluation shows a thyroid-stimulating hormone (TSH) level of 2.1 µU/mL (normal: 0.5-5.0 µU/mL) and a normal free T4 level. Which of the following is the most appropriate initial pharmacotherapy for this patient?

Show answer & explanation

Answer: Quetiapine

Answer

The most appropriate initial pharmacotherapy is quetiapine, as the patient is experiencing a bipolar depressive episode.
The correct answer is quetiapine. This patient is currently experiencing a major depressive episode, but his history of a distinct 2-week period of elevated energy, decreased need for sleep, pressured speech, and severe impulsivity indicates a past manic episode. Therefore, his correct diagnosis is Bipolar I disorder, currently in a depressed phase. First-line treatments for bipolar depression include quetiapine, lurasidone, and the olanzapine-fluoxetine combination. These agents effectively target depressive symptoms without significantly increasing the risk of a manic switch.

Step-by-Step Solution

1
Evaluate the current symptom profile.
The patient has a 6-week history of fatigue, hypersomnia, weight gain, guilt, and low energy, which meets the criteria for a major depressive episode with atypical features.
Establishing the current affective state is the first step in psychiatric diagnosis.
2
Analyze the collateral history provided by the sister.
The patient had a distinct 2-week period of decreased need for sleep, pressured speech, and severe impulsivity (emptying his savings).
All patients presenting with depression must be screened for past manic or hypomanic episodes to differentiate unipolar from bipolar depression.
3
Synthesize the timeline and severity to establish the primary diagnosis.
A history of at least one manic episode (lasting ≥1 week with marked impairment) establishes the diagnosis of Bipolar I disorder. The current presentation is a bipolar depressive episode.
Bipolar I disorder requires at least one manic episode; depressive episodes are common but not required for the diagnosis, though they often dominate the clinical course.
4
Select the appropriate pharmacotherapy.
First-line treatments for bipolar depression include quetiapine, lurasidone, or the olanzapine-fluoxetine combination.
These agents effectively target depressive symptoms without significantly increasing the risk of a manic switch, unlike SSRI monotherapy.

Key Concept

Patients presenting with a major depressive episode must be screened for a history of mania or hypomania to distinguish Bipolar Disorder from Major Depressive Disorder, as treatment pathways differ significantly.
Estimated Time:1m 30s
Question 67Question →

A 6868-year-old man is brought to the geriatric clinic by his daughter for a follow-up evaluation. For the past 33 months, he has experienced profound sadness, anhedonia, early morning awakenings, and a 66-kg (1313-lb) weight loss. Three weeks ago, he began stating that his "stomach has turned to dust" and now frequently refuses to eat.

Three weeks ago, his primary care physician diagnosed a major depressive episode and prescribed citalopram. The patient took it for 1414 days but stopped it entirely 77 days ago because "it wasn't doing anything." His past medical history includes severe osteoarthritis, for which he takes daily tramadol.

His daughter privately reports that when the patient was 3232 years old, he had a distinct 66-week period where he slept only 22 hours a night, exhibited pressured speech, and impulsively bought two boats, which led to a brief psychiatric hospitalization.

Vital signs are within normal limits. Physical examination is unremarkable.
Laboratory results show:
- Thyroid-stimulating hormone (TSH): 1.21.2 μ\mu U/mL (normal: 0.40.4–4.04.0 μ\mu U/mL)
- Free thyroxine (T4): 0.50.5 ng/dL (normal: 0.90.9–2.42.4 ng/dL)

Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate quetiapine

Answer

The most appropriate next step is to initiate quetiapine to treat bipolar depression with psychotic features.
The correct answer is to initiate quetiapine. This patient presents with a severe depressive episode characterized by melancholic and psychotic features (nihilistic delusions). However, his remote history of an episode involving decreased need for sleep, grandiosity, and hospitalization meets the criteria for a manic episode. Therefore, his true diagnosis is Bipolar I disorder, currently in a severe depressive episode. First-line treatments for bipolar depression that also effectively target psychotic symptoms include atypical antipsychotics such as quetiapine or lurasidone.

Step-by-Step Solution

1
Analyze the patient's current psychiatric presentation.
The patient meets criteria for a major depressive episode with psychotic features (nihilistic delusions, specifically Cotard's syndrome).
This establishes the severity of the current episode and the need to target both mood and psychosis.
2
Evaluate the patient's psychiatric history.
The history of a manic episode (decreased sleep, impulsivity, hospitalization at age 3232) changes the primary diagnosis from Major Depressive Disorder to Bipolar I Disorder.
A single manic episode is sufficient to diagnose Bipolar I Disorder, fundamentally altering the pharmacologic approach to depressive episodes.
3
Assess the pharmacological context and laboratory findings.
The patient prematurely stopped citalopram (which was actually protective against a manic switch), takes tramadol (serotonergic risk), and has central hypothyroidism (normal TSH, low T4).
This rules out resuming SSRIs, initiating MAOIs (due to drug interactions), and treating for primary hypothyroidism.
4
Select the optimal treatment for the established diagnosis.
Quetiapine is selected as it is FDA-approved for bipolar depression and provides antipsychotic coverage.
It treats both the bipolar depression and the psychotic features without the risk of antidepressant-induced mania.

Key Concept

Patients presenting with a major depressive episode must be meticulously screened for a history of mania; if present, the diagnosis is Bipolar Disorder, and antidepressant monotherapy should be avoided in favor of agents like quetiapine, lurasidone, or lithium.
Estimated Time:2m 0s
Question 68Question →

A 26-year-old man comes to the clinic for a follow-up visit. Three weeks ago, he was diagnosed with major depressive disorder after presenting with a 6-week history of depressed mood, anhedonia, significant weight loss, and severe fatigue. At his initial evaluation, a comprehensive psychiatric history confirmed the absence of any past episodes of abnormally elevated mood, impulsivity, or decreased need for sleep. He was started on sertraline 50 mg daily. Today, the patient reports that his sleep has improved slightly, but he still feels sad most days and lacks the energy to resume his usual hobbies. He denies suicidal ideation, auditory hallucinations, or racing thoughts. His vital signs and physical examination are unremarkable. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Continue sertraline at the current dosage and reassess in 2 to 3 weeks

Answer

Continue sertraline at the current dosage and reassess in 2 to 3 weeks
The correct course of action is to continue the current medication and wait. Selective serotonin reuptake inhibitors (SSRIs) generally require 4 to 6 weeks to achieve their full therapeutic effect. Because this patient is only at week 3 of treatment, has already demonstrated slight clinical improvement (improved sleep), and is tolerating the medication well without adverse effects or worsening suicidality, it is premature to increase the dose, augment the medication, or switch to a different class.

Step-by-Step Solution

1
Evaluate the patient's current diagnosis and treatment duration.
The patient has unipolar major depressive disorder and has been taking an SSRI (sertraline) for exactly 3 weeks.
Establishing the timeline of treatment is critical for evaluating the efficacy of pharmacotherapy in psychiatry.
2
Assess the clinical response and tolerability.
The patient shows slight improvement (better sleep) and no reported adverse effects or worsening of symptoms.
This confirms the medication is being tolerated and has begun to show early signs of clinical benefit.
3
Apply pharmacological knowledge of SSRI onset of action.
SSRIs require 4 to 6 weeks for a full therapeutic trial. Therefore, changing the regimen at 3 weeks is premature.
Brain neuroplasticity and receptor downregulation take several weeks to translate increased synaptic serotonin into maximal mood improvement.

Key Concept

Selective serotonin reuptake inhibitors (SSRIs) typically require an adequate trial of 4 to 6 weeks at a therapeutic dose to achieve maximal clinical efficacy in treating major depressive disorder.
Estimated Time:1m 0s
Question 69Question →

During a follow-up visit at the university health center, a 24-year-old graduate student reports persistent feelings of profound sadness and lack of motivation that have severely impacted her studies over the past eight weeks. She mentions sleeping 11 to 13 hours daily, a recent 5-kg (11-lb) weight gain, and a sensation that her limbs are "made of lead." Two weeks prior to this visit, a physician prescribed citalopram. The patient reveals she abruptly stopped taking it three days ago due to mild nausea and a belief that "the pills were completely useless." While exploring her psychiatric history, she mentions a distinct 2-day period during her freshman year when she felt "euphoric and full of energy," requiring only a few hours of sleep while celebrating the end of final exams with friends. Her mood returned to baseline shortly after the weekend. She currently takes no medications and uses no illicit substances. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Reinitiate citalopram and advise that therapeutic benefits typically require four to six weeks

Answer

The correct approach is to reinitiate citalopram and advise the patient that therapeutic benefits typically require four to six weeks.
The patient is experiencing a major depressive episode with atypical features (hypersomnia, hyperphagia, leaden paralysis). Her 2-day period of euphoria following exams was a normal situational response, not a hypomanic episode (which explicitly requires a duration of at least 4 consecutive days). Her lack of response to citalopram is due to premature discontinuation, as she only took the medication for approximately 11 days. Antidepressants typically require an adequate trial of 4 to 6 weeks to achieve clinical efficacy. Mild gastrointestinal side effects like nausea are common early in SSRI therapy and usually resolve spontaneously. Educating the patient on this timeline and reinitiating the medication is the most appropriate next step.

Step-by-Step Solution

1
Analyze the patient's current clinical presentation.
The patient exhibits a 2-month history of depressed mood, hypersomnia, hyperphagia, and leaden paralysis, which firmly establishes a diagnosis of a Major Depressive Episode with atypical features.
Establishing the current syndrome is necessary to determine baseline treatment requirements.
2
Evaluate the psychiatric history for prior mood episodes to rule out bipolar disorder.
The patient experienced a 2-day period of euphoria and decreased need for sleep after final exams. This represents a normal, situational celebratory response and falls short of the strict 4-day minimum duration criteria required for a true hypomanic episode.
Differentiating unipolar depression from bipolar depression is critical, as SSRI monotherapy is safe for unipolar depression but contraindicated in bipolar disorder.
3
Assess the adequacy of the current psychopharmacological trial.
The patient took citalopram for approximately 11 days before stopping due to perceived inefficacy and mild nausea. An adequate antidepressant trial requires 4 to 6 weeks at a therapeutic dose.
Identifying premature drug discontinuation dictates that the provider should educate the patient rather than prematurely changing the medication class or dose.
4
Determine the safest and most appropriate next step in management.
Reinitiating citalopram while educating the patient on the delayed onset of action and the typically transient nature of mild gastrointestinal side effects is the standard of care.
This prevents unnecessary polypharmacy, avoids dangerous drug interactions (like serotonin syndrome with MAOIs), and ensures an evidence-based treatment timeline is followed.

Key Concept

An adequate trial of an antidepressant requires 4 to 6 weeks at a therapeutic dose; mild early side effects should be managed with reassurance, and a thorough history must confirm that prior mood elevations were normal situational responses rather than true hypomania.
Estimated Time:1m 30s
Question 70Question →

A 68-year-old woman is brought to the emergency department by her son due to progressive behavioral changes over the past 5 weeks. She has developed profound sadness, anhedonia, and terminal insomnia, typically waking at 3:00 AM and unable to return to sleep. For the past week, she has refused all food and water, repeatedly stating, "My stomach has turned to dust, it cannot process anything." She has lost 6 kg (13.2 lbs) during this period. Her medical history is significant for Parkinson disease, for which she has been taking carbidopa-levodopa and selegiline for three years.

Vital signs show a blood pressure of 96/60 mmHg and a heart rate of 112/min. Physical examination reveals severely dry mucous membranes and decreased skin turgor.

Laboratory studies show:
TestResultReference Range
Sodium152 mEq/L136-145 mEq/L
Blood urea nitrogen45 mg/dL7-18 mg/dL
Creatinine1.6 mg/dL0.6-1.2 mg/dL
Thyroid-stimulating hormone (TSH)0.1 µU/mL0.5-5.0 µU/mL
Free thyroxine (T4)0.5 ng/dL0.9-1.7 ng/dL

Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Admit for intravenous hydration and electroconvulsive therapy (ECT)

Answer

Admit for intravenous hydration and electroconvulsive therapy (ECT)
This patient presents with a severe episode of Major Depressive Disorder (MDD) with psychotic features (Cotard delusion, i.e., the belief that her stomach has turned to dust) and melancholic features (terminal insomnia, profound weight loss). Her absolute refusal to eat or drink has resulted in severe dehydration, hypernatremia, and prerenal azotemia, representing a life-threatening psychiatric emergency. In cases of psychotic depression complicated by active starvation, severe suicidality, or when standard medications are contraindicated, Electroconvulsive therapy (ECT) is the gold-standard treatment due to its rapid onset and high efficacy. Intravenous hydration must be provided concurrently to stabilize her medical condition.

Step-by-Step Solution

1
Identify the primary psychiatric syndrome based on the clinical presentation.
The patient has 5 weeks of melancholic depression and recent onset of somatic delusions, leading to a diagnosis of Major Depressive Disorder (MDD) with psychotic features.
Accurate diagnosis is required to guide psychopharmacologic or procedural interventions.
2
Assess clinical acuity and immediate life threats.
The patient's delusion has led to absolute food and fluid refusal, resulting in severe dehydration (hypernatremia) and acute kidney injury (prerenal azotemia).
Conditions involving active starvation or imminent danger to self necessitate rapid, aggressive intervention.
3
Evaluate the patient's medication list for potential pharmacological constraints.
The patient takes selegiline, a monoamine oxidase B (MAO-B) inhibitor. Initiating standard first-line therapies for psychotic depression (like SSRIs or SNRIs) is strictly contraindicated.
Combining serotonergic agents with an MAOI carries a high risk of precipitating fatal serotonin syndrome.
4
Determine the optimal intervention balancing efficacy, speed, and safety.
Electroconvulsive therapy (ECT) combined with supportive medical care (IV hydration) is the safest and most effective choice.
ECT provides rapid symptom relief for life-threatening psychotic depression and bypasses the dangerous drug-drug interactions posed by her Parkinson disease medications.

Key Concept

Management of severe major depressive disorder with psychotic features and life-threatening food refusal
Question 71Question →

A 28-year-old woman, 3 months postpartum, is brought to the clinic by her husband for a psychiatric evaluation. She has been exclusively formula-feeding her infant. For the past 4 weeks, she has experienced profound sadness, frequent crying spells, excessive sleepiness, and an inability to care for her baby. She states, "I am a terrible mother and my baby deserves better." Three weeks ago, her obstetrician prescribed sertraline, but she discontinued it after 5 days because she "felt it wasn't working fast enough." Her husband notes that 4 years ago, she had a 2-week period where she slept only 2 hours a night, spoke rapidly, and claimed she was chosen by God to lead a new religion; this episode required a brief psychiatric hospitalization. Her temperature is 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}), blood pressure is 110/70 mm Hg110/70 \text{ mm Hg}, and pulse is 78/min78/\text{min}. Physical examination is unremarkable. Laboratory studies show a thyroid-stimulating hormone (TSH) level of 1.5 μU/mL1.5 \ \mu\text{U/mL} (normal: 0.5−5.00.5-5.0). She is currently taking no medications. Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Initiate lurasidone therapy

Answer

Initiate lurasidone therapy
The patient is currently experiencing a major depressive episode, but her clear history of a 2-week manic episode with psychotic features (delusions of being chosen by God) requiring hospitalization establishes a definitive diagnosis of Bipolar I disorder. Therefore, her current presentation is bipolar depression. First-line pharmacologic treatment for acute bipolar depression includes specific atypical antipsychotics such as lurasidone, quetiapine, or cariprazine. These medications effectively target depressive symptoms in bipolar disorder without the high risk of precipitating a manic episode.

Step-by-Step Solution

1
Evaluate the current clinical presentation and psychiatric history.
The patient meets criteria for a major depressive episode, but her history of a 2-week period with decreased need for sleep, rapid speech, grandiosity, and psychotic features confirms an underlying diagnosis of Bipolar I disorder.
Establishing the correct diagnosis (Bipolar I disorder, current episode depressed) is essential to distinguish it from unipolar major depressive disorder before selecting pharmacotherapy.
2
Analyze prior medication trials and assess risks.
The patient previously received sertraline (an SSRI), which she prematurely discontinued. Restarting an SSRI as monotherapy is contraindicated in bipolar disorder due to the high risk of iatrogenic manic switching.
Recognizing the danger of antidepressant monotherapy in bipolar patients prevents severe adverse outcomes like acute mania.
3
Select the most appropriate pharmacotherapy for bipolar depression.
Lurasidone is selected.
Atypical antipsychotics (such as lurasidone, quetiapine, or cariprazine) are FDA-approved first-line treatments for acute bipolar depression.

Key Concept

Patients presenting with a major depressive episode must be carefully screened for a history of mania or hypomania; if a bipolar disorder diagnosis is established, antidepressant monotherapy should be avoided and first-line bipolar depression agents (e.g., lurasidone, quetiapine) should be initiated.
Estimated Time:1m 30s
Question 72Question →

Match each patient's clinical presentation with the most appropriate next step in management or pharmacotherapy.

Click a left item, then click its matching right item

Items

A 31-year-old woman with 4 weeks of severe depression and anhedonia; history reveals a past 6-day episode of decreased need for sleep, grandiosity, and impulsive spending.
A 74-year-old man with 1 month of profound depression, delusions of poverty, and refusal to eat or drink resulting in severe dehydration and acute kidney injury.
A 45-year-old woman with major depressive disorder, previously well-controlled on paroxetine, who was recently diagnosed with breast cancer and initiated on adjuvant tamoxifen therapy.
A 60-year-old man developing major depressive disorder 4 weeks after a myocardial infarction; he requires pharmacotherapy but has a left ventricular ejection fraction of 35%.
A 21-year-old man presenting with 2 weeks of depressed mood, profound fatigue, hypersomnia, and increased appetite, which began 4 days after abruptly discontinuing his prescribed high-dose amphetamines.

Matches

Show answer & explanation

Answer

The clinical scenarios map to specific management branch points: bipolar depression (quetiapine/lurasidone), life-threatening psychotic depression (ECT), CYP2D6 drug interactions (switch from paroxetine), post-myocardial infarction depression (sertraline), and amphetamine withdrawal (supportive care).
Each clinical vignette tests a critical, high-yield branch point in the management of depressive presentations. The 31-year-old patient has unrecognized bipolar II disorder, requiring bipolar-specific agents (quetiapine/lurasidone) rather than SSRI monotherapy to avoid mood destabilization. The 74-year-old patient has severe psychotic depression with life-threatening starvation, making ECT the treatment of choice due to its rapid onset and high efficacy. The 45-year-old patient is taking tamoxifen, which requires CYP2D6 for activation; paroxetine is a strong CYP2D6 inhibitor and must be switched to an agent with minimal inhibition like venlafaxine. The 60-year-old patient requires depression treatment post-myocardial infarction, where sertraline is the evidence-based SSRI of choice due to excellent cardiovascular safety. The 21-year-old patient is experiencing amphetamine withdrawal, which mimics atypical depression but is a substance-induced, self-limiting condition that requires only supportive care.

Step-by-Step Solution

1
Evaluate the 31-year-old woman's history of a distinct 6-day episode of decreased sleep and grandiosity.
Diagnose bipolar II disorder, current episode depressed.
Screening for past hypomania/mania is critical before treating depression to avoid precipitating a manic switch with antidepressant monotherapy.
2
Assess the 74-year-old man's psychotic features combined with his refusal to eat.
Identify a life-threatening psychiatric emergency.
Severe physical compromise (starvation, acute kidney injury) in the context of psychotic depression requires the most rapid and effective intervention, which is ECT.
3
Analyze the drug-drug interaction between paroxetine and tamoxifen in the 45-year-old woman.
Identify paroxetine as a strong CYP2D6 inhibitor that drastically reduces tamoxifen's therapeutic efficacy.
Tamoxifen is a prodrug requiring CYP2D6 for conversion to its active anti-estrogen metabolite (endoxifen); a non-inhibiting alternative antidepressant must be chosen.
4
Determine the safest antidepressant for the 60-year-old man post-myocardial infarction with a reduced ejection fraction.
Select sertraline as the optimal pharmacotherapy.
Sertraline has an extensively established cardiovascular safety profile in patients with recent ischemic heart disease, unlike tricyclics or citalopram (which prolongs QTc).
5
Differentiate the etiology of the 21-year-old man's depressive symptoms occurring strictly after discontinuation of amphetamines.
Diagnose amphetamine withdrawal rather than a primary major depressive episode with atypical features.
Amphetamine 'crash' presents with profound depression, hypersomnia, and hyperphagia, but the temporal link to discontinuation indicates a self-limiting toxidrome requiring only supportive care.

Key Concept

The precise management of depressive disorders requires careful differentiation of unipolar vs. bipolar illness, recognition of life-threatening emergencies requiring ECT, mitigation of critical drug interactions (e.g., CYP2D6), understanding of cardiovascular safety, and distinguishing primary depression from substance withdrawal.
Question 73Question →

Match each patient's clinical presentation with the most appropriate tailored pharmacotherapy or neuromodulation therapy.

Click a left item, then click its matching right item

Items

A 28-year-old woman, 3 weeks postpartum, presenting with mutism, refusal to eat or drink, and delusions that her internal organs are rotting.
A 65-year-old man, 4 weeks post-myocardial infarction, with pervasive low mood and anhedonia; recent ECG shows a QTc interval of 470 ms.
A 34-year-old woman with major depressive disorder on a maximum dose of venlafaxine, reporting resolved tearfulness but persistent profound fatigue, hypersomnia, and a 5-kg (11-lb) weight gain.
A 42-year-old man with a major depressive episode characterized by prominent early morning awakenings, severe anorexia with a 6-kg (13-lb) weight loss, and marked agitation.
A 24-year-old man presenting with severe low mood and psychomotor retardation; history reveals a distinct 5-day period last year of decreased need for sleep, pressured speech, and grandiose spending sprees.

Matches

Show answer & explanation

Answer

Clinical profiles are matched to specific treatments based on symptom clusters (e.g., mirtazapine for insomnia/anorexia, bupropion for fatigue/weight gain), medical comorbidities (sertraline for post-MI with prolonged QTc), acuity (ECT for life-threatening psychosis/inanition), and underlying diagnosis (quetiapine for bipolar depression).
Each correct match optimizes the therapeutic index by utilizing the specific side effect profile or mechanism of action of a psychiatric intervention to address the patient's unique comorbidities and symptom presentation.

Step-by-Step Solution

1
Identify the primary clinical challenge for each patient.
Patient 1: Psychosis/inanition. Patient 2: Cardiac risk. Patient 3: Residual atypical symptoms. Patient 4: Insomnia/anorexia. Patient 5: Bipolar II depression.
Depression management must be tailored to specific symptom profiles and medical histories, rather than using a single algorithm.
2
Select the treatment with a mechanism or side-effect profile that directly addresses the challenge.
ECT for rapid response; Sertraline for cardiac safety; Bupropion for activation; Mirtazapine for sedation/appetite; Quetiapine for bipolar depression.
Aligning treatment properties with patient needs maximizes efficacy and minimizes harm.

Key Concept

Tailored pharmacotherapy and neuromodulation in depressive disorders based on side effect profiles, medical comorbidities, and diagnostic history.
Question 74Question →

Match each patient's clinical vignette to the most accurate psychiatric diagnosis.

Click a left item, then click its matching right item

Items

A 32-year-old woman reports feeling low and hopeless for most of her life. For the past three years, she has experienced poor energy and low self-esteem on most days, without any symptom-free periods lasting more than a month.
A 24-year-old man presents with depressed mood and anxiety that started one month after his fiancée ended their engagement. He continues to work but feels highly distressed; he does not meet full criteria for a major depressive episode.
A 45-year-old woman with systemic lupus erythematosus presents with acute onset of severe depression and anhedonia two weeks after starting a high-dose oral glucocorticoid regimen for a recent disease flare.
A 29-year-old woman reports marked affective lability, irritability, and increased appetite that repeatedly occur during the week prior to menstruation and reliably resolve within a few days of follicular phase onset.

Matches

Show answer & explanation

Answer

Match the 32-year-old with chronic symptoms to persistent depressive disorder, the 24-year-old with recent stress to adjustment disorder, the 45-year-old on steroids to medication-induced depressive disorder, and the 29-year-old with cyclical symptoms to premenstrual dysphoric disorder.
Each diagnosis in the differential of depressive disorders has distinct requirements regarding timeline, triggers, and severity. Persistent depressive disorder requires at least 2 years of symptoms. Adjustment disorder requires an identifiable stressor within 3 months and sub-threshold symptoms for a major depressive episode. Medication-induced depressive disorder requires a plausible pharmacological trigger, such as systemic corticosteroids. Premenstrual dysphoric disorder requires symptoms strictly linked to the luteal phase of the menstrual cycle.

Step-by-Step Solution

1
Analyze the first vignette's timeline.
The patient has 3 years of chronic depressive symptoms without a 2-month break.
Chronicity of 2 or more years is the defining feature of persistent depressive disorder.
2
Evaluate the second vignette's inciting event and symptom severity.
Symptoms began shortly after a breakup and do not meet major depressive disorder criteria.
This presentation meets the criteria for adjustment disorder with depressed mood.
3
Assess the third vignette's clinical context.
Severe depressive symptoms emerged shortly after initiating high-dose glucocorticoids.
Corticosteroids are a classic trigger for medication-induced depressive or psychotic symptoms.
4
Review the fourth vignette's symptom pattern.
Mood lability and irritability are strictly tied to the luteal phase of the menstrual cycle.
This cyclical pattern is the absolute requirement for diagnosing premenstrual dysphoric disorder.

Key Concept

Differential diagnosis of depressive disorders based on symptom duration, inciting stressors, and cyclical patterns.
Question 75Question →

A 45-year-old man presents to the clinic with a 6-week history of persistently depressed mood, profound anhedonia, terminal insomnia, 5-kg (11-lb) weight loss, and difficulty concentrating. He denies any suicidal ideation and exhibits no psychotic features. He has no prior psychiatric or medical history and is currently treatment-naive. Based on standard clinical guidelines, arrange the following management steps in the most appropriate chronological sequence for this patient. Assume that at each subsequent step, the patient experiences an inadequate clinical response despite adequate trial duration, documented medication adherence, and good tolerability.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct clinical sequence is: 1) Screen for bipolar disorder, 2) Initiate an SSRI, 3) Optimize the SSRI dose, 4) Augment or switch antidepressants, and 5) Refer for ECT.
The standard stepped-care algorithm for major depressive disorder (MDD) begins with accurate diagnosis, which strictly requires ruling out bipolar disorder to prevent antidepressant-induced mania. Once confirmed as unipolar depression, a first-line agent (e.g., SSRI, SNRI, bupropion, mirtazapine) is initiated. If the initial dose yields a partial or non-response after an adequate duration (typically 4-6 weeks) with good tolerability, optimizing the dose of the current agent is preferred. If maximizing the dose fails, the next step involves switching to a different antidepressant class or augmenting with a second-line agent (e.g., aripiprazole, lithium). Finally, electroconvulsive therapy (ECT) or other neuromodulation therapies are indicated for true treatment-resistant depression, defined as the failure of at least two adequate trials of different pharmacotherapies in the absence of psychiatric emergencies (where ECT might be moved to first-line).

Step-by-Step Solution

1
Assess diagnostic criteria and definitively rule out bipolar disorder.
The patient is screened for past manic or hypomanic episodes.
Unopposed antidepressants can precipitate mania in patients with underlying but undiagnosed bipolar disorder.
2
Initiate first-line pharmacotherapy.
An SSRI or other first-line antidepressant is prescribed.
This is the standard initial evidence-based treatment for moderate-to-severe unipolar major depressive disorder.
3
Manage the initial inadequate response.
The dose of the initial SSRI is increased to the maximum tolerated dose.
Patients often require dose titration to achieve clinical remission; a trial should not be abandoned prematurely if the drug is well tolerated.
4
Manage the failure of an optimized initial monotherapy.
An augmenting agent (e.g., a second-generation antipsychotic) is added, or the drug class is switched.
Failure of an optimized first-line agent requires a change in pharmacologic strategy to achieve remission.
5
Manage true treatment-resistant depression (TRD).
The patient is referred for electroconvulsive therapy (ECT).
ECT is indicated for depression that has failed multiple adequate pharmacologic trials in a non-emergent setting, establishing a diagnosis of TRD.

Key Concept

Stepped-care treatment algorithm for Major Depressive Disorder (MDD) and Treatment-Resistant Depression
Question 76Question →

Match each patient's clinical presentation with the most appropriate next step in management or specific therapeutic intervention.

Click a left item, then click its matching right item

Items

An elderly individual in an acute severe depressive episode who is actively refusing food and fluids, presenting with severe dehydration and delusions of guilt.
A young adult presenting with profound sadness and psychomotor retardation, whose history includes a prior distinct episode of grandiosity, decreased need for sleep, and pressured speech lasting six days.
A patient with major depressive disorder who has shown only a partial response to an adequate 8-week trial of escitalopram, with persistent residual symptoms of fatigue and low motivation.
A healthy professional with a first-time episode of mild major depressive disorder who explicitly declines the use of any psychotropic medications.

Matches

Show answer & explanation

Answer

The clinical presentations map to their respective best management steps: the food-refusing elderly patient requires electroconvulsive therapy; the patient with past mania needs quetiapine monotherapy; the partial SSRI responder with fatigue benefits from bupropion augmentation; and the medication-averse patient should receive cognitive behavioral therapy.
Each matching pair accurately aligns the patient's unique clinical context (e.g., life-threatening symptoms, bipolar history, medication side effect profile, personal preference) with current psychiatric treatment guidelines.

Step-by-Step Solution

1
Evaluate the elderly patient's presentation for life-threatening features.
The patient has severe dehydration and delusions, indicating depression with psychotic features and imminent physical danger.
Immediate, rapid-acting interventions like ECT are necessary when depression threatens the patient's life through starvation or high suicide risk.
2
Analyze the young adult's psychiatric history prior to the depressive episode.
The history of grandiosity, decreased sleep, and pressured speech confirms a past manic episode, diagnosing Bipolar I Disorder.
Recognizing underlying bipolarity is critical to avoid prescribing antidepressant monotherapy, which can precipitate a manic switch.
3
Assess the treatment response of the patient on escitalopram.
The patient has a partial response but persistent fatigue and low motivation.
A partial response warrants augmentation; bupropion targets dopamine and norepinephrine, effectively treating residual fatigue without adding serotonergic side effects.
4
Incorporate the mild depression patient's treatment preferences.
The patient declines medication but needs treatment for an active depressive episode.
Evidence-based psychotherapy like CBT is equal in efficacy to medications for mild-to-moderate depression and honors patient autonomy.

Key Concept

Treatment selection in depressive disorders depends heavily on illness severity, the presence of psychotic or bipolar features, prior treatment responses, and patient preference.
Question 77Question →

A 38-year-old female presents to the clinic with an 8-week history of depressed mood, significant weight loss, early morning awakenings, and severe anhedonia, causing her to take a leave of absence from work. Over the subsequent 14 months, her clinical condition progresses through multiple phases of treatment resistance, eventually culminating in a psychiatric admission for active suicidal ideation with a specific plan. Arrange the following clinical actions in the correct chronological sequence according to evidence-based management guidelines for this patient's evolving condition, from her initial presentation through her eventual inpatient admission.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with screening for bipolar disorder, followed by an adequate SSRI trial, switching to an SNRI due to non-response, augmenting the SNRI for partial response, and finally utilizing ECT for the emergent, refractory suicidal crisis.
The standard psychiatric algorithm for MDD requires a systematic escalation. Safety is the first priority, making bipolar screening the required initial action. Next, an adequate trial of a first-line agent (SSRI) is necessary, avoiding premature discontinuation. If there is no response, switching to another monotherapy (SNRI) is indicated. If that subsequent trial yields only a partial response, augmentation (e.g., atypical antipsychotic) is added. Finally, if the patient becomes refractory and develops life-threatening features (active suicidality), emergency intervention with ECT is the definitive treatment of choice.

Step-by-Step Solution

1
Screen for a history of mania or hypomania.
Bipolar disorder is ruled out.
Administering unopposed antidepressants to a patient with bipolar disorder can precipitate a manic episode. Screening is the absolute first step.
2
Initiate first-line SSRI monotherapy for 4 to 6 weeks.
Patient completes an adequate trial with no clinical response.
Antidepressants take time to downregulate receptors and exhibit clinical effect; a 4-6 week trial prevents premature drug discontinuation.
3
Switch to a different monotherapy class (e.g., SNRI).
Patient achieves only a partial response after another adequate trial.
When there is zero response to a first-line agent, switching to a different medication is standard protocol.
4
Augment the SNRI with a second-generation antipsychotic.
Patient eventually deteriorates despite combination therapy, becoming acutely suicidal.
Augmentation is preferred when a patient has a partial response to avoid losing the slight improvements gained.
5
Admit to psychiatry and administer ECT.
Rapid stabilization of the life-threatening crisis.
ECT provides the most rapid and effective response for severe, treatment-resistant depression with acute suicidality.

Key Concept

Stepped-care management of Major Depressive Disorder, from initial safety screening through adequate medication trials, to emergency neuromodulation.
Question 78Question →

A 32-year-old woman is brought to the emergency department by her sister due to a 3-week history of worsening social withdrawal, profound sadness, and extreme fatigue. The patient sleeps up to 15 hours a day and frequently states, "Everyone would be better off without me." Her sister notes the patient recently stopped attending her job as an accountant.

Review of her medical history reveals a depressive episode three years ago, for which her primary care physician prescribed fluoxetine. Three weeks into that treatment, the patient abruptly quit a previous job, flew to another continent alone, and spent her entire life savings over the course of seven days while sleeping less than two hours per night. She was hospitalized abroad, the fluoxetine was discontinued, and her mood gradually stabilized over the next month.

The patient currently takes no medications and uses no illicit substances. Vital signs are within normal limits. Physical examination reveals a flat affect and psychomotor retardation.

Laboratory results are as follows:
TestResultReference Range
Thyroid-stimulating hormone (TSH)4.2 mU/L0.5 - 5.0 mU/L
Free thyroxine (T4)1.1 ng/dL0.9 - 1.7 ng/dL

Which of the following is the most appropriate next step in the pharmacologic management of this patient?

Show answer & explanation

Answer: Initiate quetiapine therapy

Answer

The most appropriate next step is to initiate quetiapine therapy.
The correct intervention is to initiate quetiapine therapy. Although this patient is currently presenting with a severe depressive episode, a thorough review of her psychiatric history reveals a diagnosis of Bipolar I Disorder. Three years ago, she experienced an antidepressant-induced manic episode characterized by a decreased need for sleep, impulsivity (spending her life savings, traveling to a foreign continent), and functional deterioration requiring hospitalization. According to DSM-5 criteria, a full manic episode that emerges during antidepressant treatment and persists beyond the physiological effect of the treatment is sufficient to diagnose Bipolar I Disorder. When a patient with Bipolar I Disorder presents with an acute depressive episode, the standard of care is to initiate a medication with established efficacy for bipolar depression, such as specific atypical antipsychotics (e.g., quetiapine, lurasidone, cariprazine) or mood stabilizers (e.g., lithium, lamotrigine). Quetiapine is an excellent first-line choice because it acts rapidly to treat both the depressed mood and the associated severe insomnia.

Step-by-Step Solution

1
Analyze the patient's current clinical presentation.
The patient is experiencing a severe major depressive episode characterized by hypersomnia, profound sadness, functional impairment, and passive suicidal ideation.
Establishing the current affective state is required before determining pharmacological needs.
2
Evaluate the psychiatric history for differentiating features between unipolar and bipolar depression.
The patient has a history of an antidepressant-induced manic episode (decreased sleep, reckless spending, impulsive travel) requiring hospitalization.
According to DSM-5, a full manic episode that emerges during antidepressant treatment and persists beyond the physiological effect of the drug establishes a diagnosis of Bipolar I Disorder.
3
Select the appropriate pharmacotherapy for acute bipolar depression.
Quetiapine (an atypical antipsychotic) is selected. Antidepressant monotherapy must be avoided.
In Bipolar I Disorder, antidepressant monotherapy is contraindicated due to the high risk of precipitating a manic switch. First-line treatments for bipolar depression include quetiapine, lurasidone, or mood stabilizers like lithium.

Key Concept

Prior to initiating pharmacotherapy for a major depressive episode, it is critical to screen for a history of mania or hypomania (including antidepressant-induced episodes). Patients with Bipolar I Disorder who present with depression should be treated with an atypical antipsychotic approved for bipolar depression (e.g., quetiapine, lurasidone) or a mood stabilizer, rather than antidepressant monotherapy.
Estimated Time:1m 30s
Question 79Question →

During a routine telehealth appointment, a 28-year-old marketing executive describes a 6-week history of worsening dysphoria, profound anhedonia, and debilitating fatigue. She reports sleeping up to 12 hours a day and experiencing a 5-kg (11-lb) weight gain over this period. The patient expresses excessive guilt over her recent decline in work performance. She has no significant past medical history and does not consume alcohol or illicit substances. The physician considers initiating pharmacotherapy with a selective serotonin reuptake inhibitor. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Elicit a history of distinct periods featuring unusually elevated mood and decreased need for sleep

Answer

Elicit a history of distinct periods featuring unusually elevated mood and decreased need for sleep
The most critical next step is to screen for a history of manic or hypomanic episodes. This patient presents with a major depressive episode, characterized by atypical features (hypersomnia, weight gain, profound fatigue). However, bipolar depression and unipolar depression cannot be reliably distinguished based solely on current depressive symptoms. Because a diagnosis of Major Depressive Disorder requires that there has never been a manic or hypomanic episode, the clinician must explicitly ask about past periods of elevated mood, impulsivity, and decreased need for sleep. Initiating antidepressant monotherapy in a patient with unrecognized bipolar disorder carries a significant risk of precipitating a manic or hypomanic episode (manic switch).

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient meets criteria for a major depressive episode (dysphoria, anhedonia, fatigue, hypersomnia, weight gain, guilt for 6 weeks).
Establishing the current syndrome is the first step in psychiatric diagnosis.
2
Determine the differential diagnosis.
The presentation could represent Major Depressive Disorder (MDD) or the depressed phase of Bipolar Disorder.
Unipolar and bipolar depression present identically during an acute depressive episode.
3
Identify the critical pre-treatment evaluation step.
Screening for a history of manic or hypomanic episodes is required.
A diagnosis of MDD requires the absence of any past manic or hypomanic episodes. Prescribing an SSRI to a patient with unrecognized bipolar disorder can precipitate a manic switch.

Key Concept

Before diagnosing Major Depressive Disorder and initiating antidepressant therapy, clinicians must screen for a lifetime history of manic or hypomanic episodes to rule out Bipolar Disorder and prevent antidepressant-induced mania.
Question 80Question →

Match each patient's comprehensive clinical vignette to the most accurate psychiatric diagnosis.

Click a left item, then click its matching right item

Items

A 19-year-old college freshman reports feeling tearful and having difficulty sleeping for the past 2 months since moving away from home. She feels overwhelmed by classes but denies anhedonia, guilt, or suicidal ideation. She is able to attend classes and feels her mood improve significantly when visiting her family.
A 28-year-old man presents with a 4-week history of severe anhedonia, hypersomnia, and feelings of worthlessness. Upon detailed screening, he reports a distinct 6-day period last year where he felt uncharacteristically energetic, slept only 3 hours a night without feeling tired, and impulsively bought a sports car he could not afford.
A 45-year-old woman develops severe depressed mood, emotional lability, and profound insomnia. These symptoms began two weeks after she was prescribed high-dose oral prednisone to manage a severe systemic lupus erythematosus flare. Prior to this, she had no history of psychiatric illness.
A 35-year-old woman presents with a 6-week history of pervasive sadness, inability to enjoy her usual hobbies, early morning awakenings, a 5-kg (11-lb) weight loss, and difficulty concentrating at work. She reports feeling guilty over minor past mistakes and states her performance at work has severely declined.

Matches

Show answer & explanation

Answer

The college student with homesickness has an adjustment disorder. The man with current depression and past hypomania has bipolar disorder. The woman on prednisone has a medication-induced depressive disorder. The woman with 6 weeks of pervasive anhedonia and somatic symptoms has major depressive disorder.
Correct diagnosis in depressive disorders relies on precise pattern recognition: distinguishing the sub-threshold, stressor-related presentation of adjustment disorder; identifying past hypomanic episodes that define bipolar disorder; recognizing temporal associations with offending agents like glucocorticoids; and confirming the full symptom cluster required for major depressive disorder.

Step-by-Step Solution

1
Analyze the timeline, symptom severity, and functional impairment of each clinical vignette.
Identified that the 19-year-old does not meet full MDD criteria and has a clear stressor. The 35-year-old fully meets MDD criteria with marked functional impairment.
Differentiating major depressive disorder from adjustment disorder requires evaluating symptom count (at least 5 for MDD) and severity of functional impairment.
2
Screen for history of elevated mood or external triggers (medications/substances).
The 28-year-old has a history of a 6-day hypomanic episode. The 45-year-old's symptoms clearly align with the initiation of high-dose corticosteroids.
Failing to identify past hypomania/mania leads to inappropriate unipolar MDD treatment, and failing to recognize medication triggers leads to unnecessary primary psychiatric diagnoses.

Key Concept

Discrimination between unipolar major depressive disorder, bipolar depression, adjustment disorder, and substance/medication-induced depressive disorder based on clinical history and timeline.
PreviousPage 4 / 6Next
Depressive Disorders Practice Questions — USMLE Step 2 CK — Page 4 | Examkin